GW Pharmaceuticals PLC- (NASDAQ:GWPH) Insider Sells $70,728.96 in Stock

GW Pharmaceuticals PLC- (NASDAQ:GWPH) insider Douglas B. Snyder sold 5,424 shares of the firm’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $13.04, for a total transaction of $70,728.96. Following the completion of the transaction, the insider now directly owns 73,740 shares of the company’s stock, valued at $961,569.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Douglas B. Snyder also recently made the following trade(s):

  • On Tuesday, July 9th, Douglas B. Snyder sold 4,968 shares of GW Pharmaceuticals PLC- stock. The shares were sold at an average price of $14.42, for a total transaction of $71,638.56.

Shares of GW Pharmaceuticals PLC- stock traded down $5.35 on Thursday, hitting $147.51. 7,271 shares of the company traded hands, compared to its average volume of 556,900. The firm’s 50-day simple moving average is $164.07 and its 200 day simple moving average is $166.78. The company has a current ratio of 8.31, a quick ratio of 7.59 and a debt-to-equity ratio of 0.03. The company has a market cap of $4.61 billion, a P/E ratio of -13.94 and a beta of 2.25. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.96. The firm had revenue of $72.04 million for the quarter, compared to analysts’ expectations of $37.28 million. GW Pharmaceuticals PLC- had a negative net margin of 101.45% and a negative return on equity of 38.09%. The business’s quarterly revenue was up 2096.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.25) EPS. Analysts predict that GW Pharmaceuticals PLC- will post -3.84 earnings per share for the current year.

Several brokerages have commented on GWPH. Piper Jaffray Companies raised their price target on shares of GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. Morgan Stanley raised their price target on shares of GW Pharmaceuticals PLC- to $238.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $229.00 price target (up from $196.00) on shares of GW Pharmaceuticals PLC- in a report on Tuesday, May 7th. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Finally, CIBC raised shares of GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a report on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $212.70.

Several institutional investors have recently bought and sold shares of the company. US Bancorp DE raised its position in shares of GW Pharmaceuticals PLC- by 0.6% during the 1st quarter. US Bancorp DE now owns 11,683 shares of the biopharmaceutical company’s stock valued at $1,969,000 after buying an additional 75 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in GW Pharmaceuticals PLC- by 14.9% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 601 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 78 shares during the period. Brandywine Oak Private Wealth LLC raised its position in GW Pharmaceuticals PLC- by 6.0% in the 1st quarter. Brandywine Oak Private Wealth LLC now owns 1,435 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 81 shares during the period. Envestnet Asset Management Inc. raised its position in GW Pharmaceuticals PLC- by 4.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 92 shares during the period. Finally, YorkBridge Wealth Partners LLC raised its position in GW Pharmaceuticals PLC- by 100.0% in the 1st quarter. YorkBridge Wealth Partners LLC now owns 200 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 100 shares during the period. Hedge funds and other institutional investors own 80.94% of the company’s stock.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

See Also: Holder of Record

Insider Buying and Selling by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.